Is astrology true and does it play a huge role in your personality.

Mumbai Terror Plot Suspect Gets Tentative Trial Date (Update1) May 11 (Bloomberg) — Terrorism suspect Tahawwur Rana, a Chicago-area businessman accused of helping plan the deadly 2008 attacks in Mumbai, may face trial in the U.S. on Nov. 1. Read more on Bloomberg

Yeah, it was indeed Salman Khans day-out at the ZOOM studio in Mumbai. He was promoting Wanted, alright, but when Sallu is at his best, hes nothing short of a super-entertainer. And thats what he did, he entertained us all and had the whole house in splits with his one-liners, his witty jibes at the media (oh, how we love him for that) and his typical dance moves. Yep, believe it or not, he was out there doing a jig for us all. And our cameras, too. The highlight of the day was when he dropped by ZOOMs editing studio and saw some of the story scripts strewn over the place. He picked up couple, raised his brows and said, Yeh kaisa script hai? Tumhare scriptwriters kaun hain? Our writers, a wee bit embarrassed, quickly responded saying it was their job, blah, blah, blah. Little did they know Sallu was simply being funny and bratty. He promptly added, Why are you guys making rotis here? Come to my place and I will feed you stories that taste like parathas. Phew! We heaved a sigh of relief. Our scriptwriters could do with some chilled beer, for starters. Wotsay, guys?

ZoomTV.in, the digital arm of Zoom Entertainment Television, is the Number One source of Bollywood video content online. It’s your one-stop source for celebrity gossip, breaking entertainment news and more.

Confident Roslinda out to confirm Delhi date
TWO competition wins this year are set to spur Roslinda Samsu to new heights in her bid to confirm her ticket to the New Delhi Commonwealth Games in October.

Read more on New Straits Times

SBI sets date for rights issue
Mumbai, March 16: The State Bank of India (SBI) will raise around Rs 20,000 crore through a rights issue by the end of this calendar year to fund its business requirements.

Read more on The Telegraph

FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission And Targets Action Date
Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company’s Complete Response submission for Prolia(TM) (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25 …

Read more on Medical News Today